Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Drug Metabolism & Disposition
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Drug Metabolism & Disposition

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit dmd on Facebook
  • Follow dmd on Twitter
  • Follow ASPET on LinkedIn
Rapid CommunicationShort Communication

Hepatocellular Disposition and Transporter Interactions with Tolvaptan and Metabolites in Sandwich-Cultured Human Hepatocytes

Yang Lu, Jason R. Slizgi, Kenneth R. Brouwer, Robert L. St. Claire, Kimberly M. Freeman, Maxwell Pan, William J. Brock and Kim L. R. Brouwer
Drug Metabolism and Disposition June 2016, 44 (6) 867-870; DOI: https://doi.org/10.1124/dmd.115.067629
Yang Lu
Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina (Y.L., J.R.S., K.L.R.B); Qualyst Transporter Solutions, Durham, North Carolina (K.R.B., R.L.S.C., K.M.F); Otsuka PDC, Inc., Rockville, Maryland (M.P.); Brock Scientific Consulting, Montgomery Village, Maryland (W.J.B.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jason R. Slizgi
Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina (Y.L., J.R.S., K.L.R.B); Qualyst Transporter Solutions, Durham, North Carolina (K.R.B., R.L.S.C., K.M.F); Otsuka PDC, Inc., Rockville, Maryland (M.P.); Brock Scientific Consulting, Montgomery Village, Maryland (W.J.B.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kenneth R. Brouwer
Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina (Y.L., J.R.S., K.L.R.B); Qualyst Transporter Solutions, Durham, North Carolina (K.R.B., R.L.S.C., K.M.F); Otsuka PDC, Inc., Rockville, Maryland (M.P.); Brock Scientific Consulting, Montgomery Village, Maryland (W.J.B.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Robert L. St. Claire
Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina (Y.L., J.R.S., K.L.R.B); Qualyst Transporter Solutions, Durham, North Carolina (K.R.B., R.L.S.C., K.M.F); Otsuka PDC, Inc., Rockville, Maryland (M.P.); Brock Scientific Consulting, Montgomery Village, Maryland (W.J.B.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kimberly M. Freeman
Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina (Y.L., J.R.S., K.L.R.B); Qualyst Transporter Solutions, Durham, North Carolina (K.R.B., R.L.S.C., K.M.F); Otsuka PDC, Inc., Rockville, Maryland (M.P.); Brock Scientific Consulting, Montgomery Village, Maryland (W.J.B.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Maxwell Pan
Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina (Y.L., J.R.S., K.L.R.B); Qualyst Transporter Solutions, Durham, North Carolina (K.R.B., R.L.S.C., K.M.F); Otsuka PDC, Inc., Rockville, Maryland (M.P.); Brock Scientific Consulting, Montgomery Village, Maryland (W.J.B.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
William J. Brock
Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina (Y.L., J.R.S., K.L.R.B); Qualyst Transporter Solutions, Durham, North Carolina (K.R.B., R.L.S.C., K.M.F); Otsuka PDC, Inc., Rockville, Maryland (M.P.); Brock Scientific Consulting, Montgomery Village, Maryland (W.J.B.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kim L. R. Brouwer
Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina (Y.L., J.R.S., K.L.R.B); Qualyst Transporter Solutions, Durham, North Carolina (K.R.B., R.L.S.C., K.M.F); Otsuka PDC, Inc., Rockville, Maryland (M.P.); Brock Scientific Consulting, Montgomery Village, Maryland (W.J.B.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF + SI
  • PDF
Loading

Abstract

Tolvaptan is a selective V2-receptor antagonist primarily metabolized by CYP 3A. The present study investigated the hepatocellular disposition of tolvaptan and the generated tolvaptan metabolites, DM-4103 and DM-4107, as well as the potential for drug-drug interactions (DDIs) with metabolic and transport proteins in sandwich-cultured human hepatocytes (SCHH). Tolvaptan was incubated with SCHH and quantified by liquid chromatography–tandem mass spectrometry. Pioglitazone, verapamil, MK-571, and elacridar were used as inhibitors to investigate mechanisms of transport and metabolism of tolvaptan and metabolites. Taurocholate (TCA), pravastatin, digoxin, and metformin were used as transporter probes to investigate which transport proteins were inhibited by tolvaptan and metabolites. Cellular accumulation of tolvaptan (0.15–50 μM), DM-4103, and DM-4107 in SCHH was concentration-dependent. Tolvaptan accumulation (15 μM) in SCHH was not altered markedly by 50 μM pioglitazone, verapamil, MK-571, or 10 μM elacridar. Coincubation of tolvaptan with pioglitazone, verapamil, MK-571, and elacridar reduced DM-4107 accumulation by 45.6, 79.8, 94.5, and 23.0%, respectively, relative to control. Coincubation with increasing tolvaptan concentrations (0.15–50 μM) decreased TCA (2.5 μM) cell+bile accumulation and the TCA biliary excretion index (BEI; from 76% to 51%), consistent with inhibition of the bile salt export pump (BSEP). Tolvaptan (15 μM) had no effect on the cellular accumulation of 2.5 μM pravastatin or metformin. Digoxin cellular accumulation increased, and the BEI of digoxin decreased from 23.9 to 8.1% in the presence of 15 μM tolvaptan, consistent with inhibition of P-glycoprotein. In summary, SCHH studies revealed potential metabolic- and transporter-mediated DDIs involving tolvaptan and metabolites.

Footnotes

    • Received October 16, 2105.
    • Accepted March 21, 2016.
  • Dr. M. Pan is an employee of Otsuka Pharmaceutical Development and Commercialization, Inc. Dr. K. R. Brouwer, Ms. K. M. Freeman, and Dr. R. L. St. Claire are employed by Qualyst Transporter Solutions, LLC. Dr. K. L. R. Brouwer is a coinventor of the sandwich-cultured hepatocyte technology for quantification of biliary excretion (B-CLEAR) and related technologies, which have been licensed exclusively to Qualyst Transporter Solutions, LLC.

  • Funding was provided by Otsuka Pharmaceutical Development and Commercialization, Inc., and by the National Institutes of Health National Institute of General Medical Sciences [Award no. R01GM041935 (K.L.R.B.)]. The content is solely the responsibility of the authors and does not necessarily represent the official views of Otsuka or the NIH.

  • dx.doi.org/10.1124/dmd.115.067629.

  • ↵Embedded ImageThis article has supplemental material available at dmd.aspetjournals.org.

  • Copyright © 2016 by The American Society for Pharmacology and Experimental Therapeutics
View Full Text

 

DMD articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Drug Metabolism and Disposition: 44 (6)
Drug Metabolism and Disposition
Vol. 44, Issue 6
1 Jun 2016
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Drug Metabolism & Disposition article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Hepatocellular Disposition and Transporter Interactions with Tolvaptan and Metabolites in Sandwich-Cultured Human Hepatocytes
(Your Name) has forwarded a page to you from Drug Metabolism & Disposition
(Your Name) thought you would be interested in this article in Drug Metabolism & Disposition.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Rapid CommunicationShort Communication

Tolvaptan Disposition and DDIs in SCHH

Yang Lu, Jason R. Slizgi, Kenneth R. Brouwer, Robert L. St. Claire, Kimberly M. Freeman, Maxwell Pan, William J. Brock and Kim L. R. Brouwer
Drug Metabolism and Disposition June 1, 2016, 44 (6) 867-870; DOI: https://doi.org/10.1124/dmd.115.067629

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Rapid CommunicationShort Communication

Tolvaptan Disposition and DDIs in SCHH

Yang Lu, Jason R. Slizgi, Kenneth R. Brouwer, Robert L. St. Claire, Kimberly M. Freeman, Maxwell Pan, William J. Brock and Kim L. R. Brouwer
Drug Metabolism and Disposition June 1, 2016, 44 (6) 867-870; DOI: https://doi.org/10.1124/dmd.115.067629
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results and Discussion
    • Authorship Contributions
    • Footnotes
    • Abbreviations
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF + SI
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Preincubation Effects on Inhibition of OCT1 by CsA
  • Carbamazepine Metabolite and Hypersensitivity Reactions
  • SULT4A1 Preserves Mitochondrial Function
Show more Short Communication

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About DMD
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Journal of Pharmacology and Experimental Therapeutics
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-009X (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics